B. Cadilha

发表

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

C. Klein, S. Endres, S. Kobold, 2018, British Journal of Cancer.

Determinants of response and resistance to CAR T cell therapy.

S. Endres, M. Subklewe, S. Kobold, 2019, Seminars in cancer biology.

Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

A. Villani, B. Medoff, M. Ligorio, 2019, Nature.

Combination of C-C chemokine receptor 8 and dominant-negative TGF-β-receptor 2 expression in T cells for adoptive T cell therapy of solid cancer

W. Zimmermann, R. Hickel, S. Endres, 2020 .

Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy

C. Klein, Jian Ding, M. Jastroch, 2019, Clinical Cancer Research.

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma

S. Endres, M. Chaloupka, S. Kobold, 2018, Front. Immunol..

Flow cytometry detection and quantification of CAR T cells into solid tumors.

S. Endres, S. Kobold, B. Cadilha, 2022, Methods in cell biology.

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

S. Endres, S. Kobold, B. Cadilha, 2019, International journal of molecular sciences.

T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

N. Halama, C. Marr, E. Tartour, 2021, Nature Biomedical Engineering.

Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy

S. Endres, S. Kobold, F. Rataj, 2017 .

Advances in cancer immunotherapy 2019 – latest trends

J. D'haese, J. Werner, V. Heinemann, 2019, Journal of Experimental & Clinical Cancer Research.

Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

A. Villani, B. Medoff, M. Ligorio, 2019, Nature.

CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment

Michael Y. Gerner, J. Billingsley, M. Pittet, 2021, Cell.

Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis

J. Dai, H. Zitzelsberger, H. Braselmann, 2019, Science Advances.

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

S. Endres, S. Kobold, S. Stoiber, 2019, Cells.

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy

D. Green, G. Cappellano, L. Boon, 2021, Journal for ImmunoTherapy of Cancer.

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1

G. Curigliano, M. Rescigno, G. Penna, 2021, Journal for ImmunoTherapy of Cancer.

T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis

R. Flavell, M. Soengas, H. Anders, 2023, Immunity.

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

C. Marr, S. Endres, T. Mempel, 2021, Science Advances.

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins

D. Busch, Theresa Kaeuferle, F. Blaeschke, 2021, Blood Cancer Journal.

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function

S. Endres, U. Schindler, S. Kobold, 2022, British Journal of Cancer.

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer

A. Straube, H. Ishikawa-Ankerhold, M. Subklewe, 2023, Oncoimmunology.

Advances in cancer immunotherapy 2019 – latest trends

J. D'haese, J. Werner, V. Heinemann, 2019, Journal of experimental & clinical cancer research : CR.

Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma

F. Klauschen, D. Anz, T. G. Grünewald, 2022, bioRxiv.

A modular and controllable T cell therapy platform for acute myeloid leukemia

C. Klein, S. Endres, M. Subklewe, 2021, Leukemia.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma

C. Bertolotto, R. Ballotti, S. Endres, 2018, Translational oncology.

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia

B. Vick, I. Jeremias, C. Marr, 2023, Nature Biotechnology.

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.

S. Endres, S. Kobold, T. Feuchtinger, 2023, British journal of cancer.

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

M. Heppt, C. Marr, S. Endres, 2023, Journal for ImmunoTherapy of Cancer.

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

C. Klein, S. Endres, S. Kobold, 2018, British Journal of Cancer.

Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

A. Villani, B. Medoff, M. Ligorio, 2019 .